Skip to content
Screener

Alumis Inc. ALMS EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Amgen logo
AmgenAMGN
$4.37+64.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$0.69+24.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$0.83+56.8%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$0.15-15.4%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$0.12+50.0%

Other financials

Income statement

See full
Revenue$1.7M-37.7%
Operating income-$148.9M-5.9%
Net income-$142.2M-340%

Balance sheet

See full
Cash & equivalents$63.7M-58.0%
Total debt$36.4M-6.1%
Total equity$452.2M-6.8%
Total assets$560.6M-8.2%

Cash flow

See full
Operating cash flow-$81.5M+23.4%
CapEx$237.0K-61.5%
Free cash flow-$81.7M+23.6%

Valuation

See full
Market cap$933.23M+126%
Enterprise value$905.95M+136%
P/S126.2×—

Profitability

See full
Operating margin-6,204.4%—
Net margin-5,933.5%—
FCF margin-4,755.3%—

Returns & leverage

See full
Return on equity-93.6%—
Debt / equity0.1×0.0×
Current ratio6.7×+0.7×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Alumis Inc.’s 10-Q, filed August 13, 2026.

Filed
Aug 13, 2026, 4:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001847367-26-000018
(in thousands, except share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net income (loss)$(142,221)$59,321$(235,274)$(39,642)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net(216)30(871)(18)
Total comprehensive income (loss)$(142,437)$59,351$(236,145)$(39,660)
Net income (loss) per share attributable to common stockholders, basic$(1.11)$0.78$(1.86)$(0.61)
Net income (loss) per share attributable to common stockholders, diluted$(1.11)$0.77$(1.86)$(0.61)
Weighted-average shares of common stock outstanding, basic127,690,25476,477,144126,377,69265,440,021
Weighted-average shares of common stock outstanding, diluted127,690,25476,635,895126,377,69265,440,021

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s EPS (diluted)?
Alumis Inc. (ALMS) reported EPS (diluted) of -$1.11 in Q2 2026.
How has Alumis Inc.'s EPS (diluted) changed year-over-year?
Alumis Inc.'s EPS (diluted) decreased by 244.2% year-over-year, from $0.77 to -$1.11.
What is the long-term trend for Alumis Inc.'s EPS (diluted)?
Over 2 years (2023 to 2025), Alumis Inc.'s EPS (diluted) has grown at a -79.4% compound annual growth rate (CAGR), from -$72.08 to -$3.05.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Alumis Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude